Friday, May 13, 2016

OncBioMune Pharmaceuticals, Inc. (OBMP: OTCQB) | Celldex Stumble Makes Space for OncBioMune at Head of Cancer Vaccines

… metastatic castrate resistant (hormone refractory) prostate cancer patients who demonstrate minimal or … prostate cancer was made based upon compelling research and belief that their prostate cancer … and present tumor antigens to activate tumor-specific T-cells, effectively slowing tumor cell growth …

No comments:

Post a Comment